Published in The Lancet, results of the phase III LITESPARK-011 clinical trial point to the combination of belzutifan plus lenvatinib…
featured news
First results from the multicenter FUSOMAP project, led by VHIO, support the potential use of Fusobacterium as a prognostic and…
CD Terrassa Hockey has donated more than 3.000€ to the Vall d’Hebron Institute of Oncology (VHIO) to support research into…
Results from the international, randomized phase III LITESPARK-022 study show that the addition of hypoxia-inducible factor-2 alpha (HIF-2 α) inhibitor…
The Iker Association has donated 10.000 euros to the Vall d’Hebron Institute of Oncology (VHIO) to continue research into myxoid…
On 8 July, Fundación Mutua Madrileña presented its 23rd Medical Research Grants, endowed with 2.3 million euros, to 21 new…
The Vall d’Hebron Institute of Oncology (VHIO) has launched an auction of artworks by artist Esperanza Pérez. This is an…
The European Society for Medical Oncology Congress on Gastrointestinal Cancers (ESMO GI) was held in Berlin from 1st to 4th…
Coinciding with World Kidney Cancer Day, on 20 June La Colla Vella dels Xiquets de Valls organised a moving event…
Published in The Lancet, results of the phase III COMPETE clinical trial show that the targeted radiotherapeutic agent [177Lu]Lu-edotreotide significantly…
